tbuckley/cabot-search huggingface dataset:
Clinical features and outcome of adjuvant chemoradiotherapy in Turkish rectal carcinoma patients: Single institution experience
Authors: F. Dane, M. Gumus, M. A. Ozturk, D. Cabuk, M. B. Atasoy, P. F. Yumuk, G. Basaran, M. S. Iyikesici, M. Teomete, U. Abacioglu, N. S. Turhal
Journal: Journal of Clinical Oncology (2008)

15103 Background: Chemoradiotherapy (CRT) after or before resection of high-risk rectal cancer (RC) improves overall survival (OS) and pelvic control. Thus, CRT is the standard adjuvant treatment in resected stage II/III RC. There are limited studies, if any, analyzing the outcome of RC patients with stage II/III who received adjuvant CRT after curative resection in Turkey. Therefore, we aimed to analyze the treatment outcome, and the prognostic significance of various parameters in these patients. Methods: 144 patients with stage II/III RC treated with adjuvant CRT since 1997 until present were analyzed retrospectively. Patients received 5-fluorouracil (375–425mg/m2/day × 5days) and calcium leucovorin (20mg/m2/day × 5days), q4weeks, two courses before and two courses after radiotherapy (RT). The 5- fluorouracil dose was reduced either to 225mg/m2/day given continuously as protracted short-term infusion during RT, or to 375–400 mg/m2/day on the first and last 4 days of RT. 45–50.4 Gy RT was given to the pelvic region. Patients were followed-up every 3 months for the first 2 years and every 6 months thereafter. Age, gender, TNM stage, and histological grade, lymphatic, vascular, and perineural invasion were analyzed as prognostic factors. Results: The median follow-up was 36 months starting from the operation date. Median age was 59 years. Forty- nine percent of the patients were node-negative. Lymphatic, vascular, and perineural invasion rate were 40%, 37.5%, and 26.3% respectively. Five-year disease-free and overall survival rates were 59.3% and 65.5%, respectively. Median overall and disease free-survival were not reached at the time of analysis. In univariate analysis T stage, node positivity, TNM stage, lymphatic invasion, and perineural invasion were independent prognostic factors for survival. In multivariate Cox regression analysis; only the presence of lymphatic invasion (p: 0.001), and vascular invasion (p: 0.01) were independent prognostic factors. Conclusion: The adjuvant treatment outcome in Turkish patients in our institution with stage II/III rectal cancer is similar to those reported in the Western studies. No significant financial relationships to disclose.
High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma: results of the European Group for Bone Marrow Transplantation.
Authors: J W Sweetenham, G Liberti, R Pearce, G Taghipour, G Santini, A H Goldstone
Journal: Journal of Clinical Oncology (1994)

PURPOSE To investigate the results of treatment and factors that affect prognosis in adult patients undergoing high-dose therapy and autologous bone marrow transplantation (ABMT) for lymphoblastic lymphoma (LBL). PATIENTS AND METHODS The study was a retrospective analysis of 214 patients reported to the Lymphoma Registry of the European Group for Bone Marrow Transplantation (EBMT) between January 1981 and December 1992, including 105 patients undergoing marrow transplantation in first complete remission (CR). Data on all patients were reviewed, and analysis of prognostic factors conducted. RESULTS The actuarial overall survival rate at 6 years for the entire group is 42%. Disease status at ABMT was the major determinant of outcome: 6-year actuarial overall survival was 63% for patients transplanted in first CR, compared with 15% for those with resistant disease at the time of transplantation. Transplantation in second CR resulted in a 31% rate of actuarial overall survival at 6 years. For patients transplanted in first CR, univariate analysis failed to identify any factors at presentation that predicted for outcome after transplantation. CONCLUSION These results suggest that ABMT is effective therapy for adults with LBL, even in patients with disease that is resistant to conventional-dose therapy. Results for patients transplanted in second CR are superior to those reported for conventional-dose salvage regimens. The results in first CR require verification in a prospective randomized clinical study.
High efficacy and low toxicity of the combination of vinorelbine and capecitabine as second line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines
Authors: G. Orphanos, A. Alexopoulos, G. Ioannidis, C. Kandylis, A. Ardavanis, J. Stavrakakis, G. Rigatos
Journal: Journal of Clinical Oncology (2006)

10719 Background: Capecitabine and Vinorelbine have shown considerable activity given as single agent or in combination with other drugs. The aim of this single institution ph.II study is to evaluate the response to the combination of Capecitabine and Vinorelbine given as second line treatment in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Methods: The regimen consists of Capecitabine 2000 mg/m 2 D1-D14 and Vinorelbine 20 mg/m 2 D1,D8 q 3 weeks for six cycles. Evaluation of response was accomplished with CT scan after the third and sixth cycle. Patients with disease progression after cycle 3 are taken off protocol. Patients with gr 2/3 granulocytopenia are given G-CSF for all subsequent cycles and there is a 20% dose reduction in both drugs for patients with gr 4 granulocytopenia. Results: 30 pts have been enrolled so far; according to statistical planning the total number of accrued pts should reach 63. Median age 55 yrs (30–76), median ECOG PS 1 (0–2), pre/postmenopausal 6/24. Number of metastatic sites: 1 in 6 pts, 2 in 15 pts, 3 in 6 pts and 4 in 3 pts. A total of 146 cycles was administered. Overall response rate 50% with CR in 2 (6.7%) pts, PR in 13 (43.3%) pts. Stable disease was observed in 4 (13.3%) pts, 8 (26.6%) pts had progressive disease and 3 (10%) were non evaluable. Toxicity: anemia gr 2 in 2 (6.7%) pts and gr 3 in 1 (3.3%) ptn, thrombocytopenia gr2 in 2 (6.7%) pts, granulocytopenia gr 2/3 in 17 (56.7%) pts and gr4 in 1 (3.3%) ptn. Gr 1/2 nausea or vomiting was observed in 5 (16.6%) pts and gr 3/4 in 2 (6.7%) pts. Vinorelbine induced phlebitis in 3 (10%) pts, gr1/2 diarrhea in 3 (10%) and fungal infection of the nail beds in 2 (6.7%) pts. Conclusions: Preleminary results suggest that the Capecitabine and Vinorelbine combination is an active and safe regimen for second line metastatic breast cancer treatment. The study remains open to achieve the planned patient accrual. No significant financial relationships to disclose.
Characteristics of assaultive patients who do and do not provide visible cues of potential violence
Authors: E D Tanke, J A Yesavage
Journal: American Journal of Psychiatry (1985)

Twelve assaultive psychiatric patients who had provided visible cues (i.e., verbal threats) of potential violence were compared on Brief Psychiatric Rating Scale factor scores with 13 patients who had not provided such cues. These groups differed from one another and from a group of 253 nonassaultive patients on one or more of the following dimensions: thinking disorder, withdrawal-retardation, anxious depression, hostile-suspiciousness, and activation. In addition, the factor scores significantly predicted the occurrence of violence among patients who did not exhibit visible cues.
Evaluating the measles immunisation campaign
Authors: N. Higson
Journal: BMJ (1995)

functions) and devolution of decisions on staffing to the local level.Crown health enterprises (similar to NHS trusts) contract for services and negotiate pay and conditions with their workers.Local pay bargaining, which is currently being debated in Britain, began to operate in the early stages of New Zealand's health reforms despite protestations by the nurses' and junior doctors' unions.Industrial action by the junior doctors'
Small cell cancer of the bladder: The Léon-Bérard Cancer Center experience
Authors: I. N. Nabil, F. Elkarak, A. Flechon, J. Droz
Journal: Journal of Clinical Oncology (2008)

16147 Background: Small cell bladder carcinoma is an uncommon tumour. In this retrospective study we report our experience dealing with this disease at Léon-Bérard Cancer Center. Methods: We retrospectively analyzed various characteristics of small cell bladder carcinoma: patient demographics, histological diagnosis, disease stage, treatment effects and outcome, in 14 non metastatic small cell bladder carcinoma patients treated at our institution between 1995 and 2006. Results: The mean age at diagnosis was 60 years (range, 45 - 77). All patients were male. Seventy-five percent were smokers. All had locally advanced disease. Ten patients (71.4%) were treated by cystoprostatectomy and bilateral pelvic lymph node resection, one by cystoprostatectomy alone. Two patients received neoadjuvant chemotherapy and four received adjuvant chemotherapy. One patient was treated by radiotherapy with concomitant cisplatin after transurethral resection of bladder tumour (TURBT). One patient refused surgery and was treated by chemotherapy alone. One patient was lost to follow-up after TURBT. After 49-month median follow up, 12 patients had relapsed. Disease-free survival was 5.7 months. The most frequent sites of relapse were the retroperitoneal lymph node (7 patients) and the liver (3 patients). Nine patients died of metastasis. Median overall survival was 29.5 months. Survival probability at 2 years was 58%. Mean overall survival was 27.2 months for all patients and 38.6 months for patients treated with cystectomy and adjuvant chemotherapy. Conclusions: To date, the optimal treatment for locally advanced small cell bladder carcinoma is not clear. Cystectomy with neoadjuvant or adjuvant chemotherapy appears as a viable option. No significant financial relationships to disclose.
The affect of the metabolic activity of the primary tumor to lymph node and distant metastasis in non-small cell lung cancer
Authors: Fatma Yildirim, Ahmet Selim Yurdakul, Murat Türk, Ümit Özgür Akdemir, Can Öztürk
Journal: European Respiratory Journal (2014)

Aim: In our study we aimed to evaluate the relationship of SUVmax of 18F FDG uptake (metabolic activity) of the primary tumor on the pretreatment PET-CT to local invasion, lymph node metastasis and distant metastasis in patients with non-small cell lung cancer (NSCLC).

Material-Method: Hospital records of 143 patients with NSCLC who were diagnosed, followed up and treated in our thoracic oncology department between March 2009-July 2013 were retrospectively analysed. Demographic features, clinical stages, SUVmax of the primary tumor on the pretreatment PET-CT, presence of local invasion, lymph node and distant metastasis of patients were recorded.

Results: Out of the 143 patients, 37 (25.8%) were at early stage (stage 1-2), 106 (74.2%) were at local-advanced stage (stage 3-4). The patients were divided into two groups based on SUVmax according to median SUVmax of 13.0; 69 patients (48.3%) had a SUVmax≥13 and 74 (51.7%) had a SUVmax<13. In the low-SUVmax group; 47 patients (63.5%) had lymph node metastasis, 33 (44.6%) has distant metastasis and 6 (8.1%) had both lymph node metastasis and distant metastasis. In the high-SUVmax group; 47 patients (68.1%) had lymph node metastasis, 27 (39.1%) has distant metastasis and 5 (7.2%) had both lymph node and distant metastasis. There were no statistically significant difference between the lymph node metastasis (p= 0.60) and distant metastasis (p=0.61) among the groups.

Conclusion: In patients with NSCLC, the SUVmax at pretreatment PET-CT, which represents the metabolic activity of the tumor, can not be used in predicting the lymph node and distant metastasis.
A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC)
Authors: S. Koshy, R. S. Herbst, C. K. Obasaju, F. Fossella, V. Papadimitrakopoulou, K. M. W. Pisters, G. Blumenschein, B. O. Peeples, W. K. Hong, R. G. Zinner
Journal: Journal of Clinical Oncology (2004)

7074
P0541 : Small intestinal permeability is elevated in chronic viral hepatitis prior to the development of cirrhosis, and is associated with the degree of fibrosis
Authors: A.S. Raj, G. Holtmann, L. Fletcher, P. Bhat, C. Tran, M. Black, K. Nath, W. Jao, D. Vesey, G.A. Macdonald
Journal: Journal of Hepatology (2015)
A customized 1600 gene expression array for the prediction of tumor response against targeted and cytotoxic drugs
Authors: A. Korrat, T. Metz, J. Schüler, M. Hofmann, N. Bausch, H. H. Fiebig
Journal: Journal of Clinical Oncology (2008)

22050 Background: In a previous study we have demonstrated a high correct prediction of xenograft testings for cytotoxic standard agents. We investigated the hypothesis that correlating drug response with gene expressions would identify gene signatures that predict the drug response of individual tumors. Methods: Cytotoxic drugs including five alkylating agents, two antimetabolites, two topoisomerase II inhibitors, two tubulin binders and the antibodies bevacizumab and cetuximab. The cytotoxic drugs were tested at their MTDs. Antitumor activity was evaluated at the minimum T/C value or after 28 days for 31–78 tumors. Tumors were considered as responsive if the different drugs effected a tumor volume inhibition to less than 11–41% (median 25%) of control tumors (T/C%). Using these criteria, on average 1/3 of the test tumors were responders and 2/3 were non-responders. Predictive gene expression signatures were determined by bioinformatic comparison of Affymetrix HG-U133 plus 2.0 profiles of responders and non-responders, verified using a leave-one-out cross- validation and for 3 drugs on an independent testing set. Results: On average, the response rate against the cytotoxic drugs for predicted responders was 83% in contrast to 34% for all tumors. Conversely, the predicted non-responders were resistant in 94% compared to 66% by random testings. For bevacizumab we obtained a 2.2-fold increase in response rate (67% vs. 30%) and for cetuximab 2,5-fold (24% vs. 61%). The correct prediction for non-response was 88% for Bevacizumab and 94% for Cetuximab. Conclusions: Prediction of tumor response to cytotoxic and antibody drugs may enhance the chance for patients to receive the best possible treatment for their cancer. Oncotest has developed a customized gene expression array (ISO17025 certified) comprising 1600 genes that predict response or resistance to 11 cytotoxic and the 2 targeted drugs. It is now evaluated in a clinical pilot study focusing on the response prediction of targeted drugs. No significant financial relationships to disclose.
Ancestim (stem cell factor, SCF) in combination with filgrastim can mobilize sufficient peripheral blood progenitor cells (PBPC) to support high-dose salvage chemotherapy and late intensification in relapsing and refractory aggressive non-Hodgkin's lymphoma. A GELA study.
Authors: C. Haioun, Augustin Ferrant, A. Van Hoof, C Thieblemont, C. Hulin, N. Mounier, H. Tilly, C. Sebban, A Allain, E. Lepage, Jean-Claude Osselaer, F Beaujean, H Vannerom, C Cailliot, André Bosly
Journal: Blood (2003)
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Authors: N Kemeny, J A Conti, K Seiter, D Niedzwiecki, J Botet, D Martin, P Costa, J Wiseberg, W McCulloch
Journal: Journal of Clinical Oncology (1992)

PURPOSE N-(phosphonacetyl)-L-aspartic acid (PALA) is a pyrimidine synthesis inhibitor that modulates fluorouracil (FU) cytotoxicity. Two previous studies of patients with colorectal carcinoma documented complete response (CR) and partial response (PR) rates of 40% and 43% using weekly low-dose PALA followed by a 24-hour FU infusion. We investigated whether comparable results could be obtained with biochemical modulation by low-dose PALA using bolus instead of infusional FU. PATIENTS AND METHODS Forty-five patients without prior chemotherapy who had advanced colorectal carcinoma were treated with PALA 250 mg/m2 followed 24 hours later by bolus FU at three dose levels, 600, 700, 800 mg/m2, repeated weekly for 6 weeks followed by a 2-week break. RESULTS The CR and PR rate was 15 of 43 patients or 35% (95% confidence interval [CI], 21% to 49%), with an overall median survival of 18 months. Grade 3 or 4 diarrhea was the major toxicity observed in 24% of patients receiving FU at 700 mg/m2 and in 43% of patients receiving 800 mg/m2. Hematologic toxicity was observed only with an FU dose of 800 mg/m2, and 29% (four of 14) of patients developed grade 4 leukopenia. We also noted the development of ascites in six patients, mild hyperbilirubinemia in 16 patients, and a decreased albumin level in 22 patients; these abnormalities occurred more frequently in responding patients. CONCLUSIONS The observed response rate, median survival, and toxicity in this study are similar to those obtained with PALA plus infusional FU and with other methods of FU modulation. Larger phase III studies are needed to compare bolus FU/PALA regimens with other PALA and non-PALA-containing combinations. Our future focus will be attenuate this regimen's toxicity while maintaining or improving its response rates and survival.
Discovery and validation of a 30-gene expression signature to identify prostate cancer patients who are candidates for active surveillance.
Authors: Travis Gerke, Svitlana Tyekucheva, Kathryn Penney, Christopher Sweeney, Rosina Lis, Howard D. Sesso, Elizabeth Nuttall, Massimo Loda, Meir J. Stampfer, Giovanni Parmigiani, Lorelei A. Mucci
Journal: Journal of Clinical Oncology (2015)

10 Background: Considerable attention has been devoted to the search for biomarkers of aggressive prostate cancer. While many promising markers have been proposed, it is often unclear whether their ability to risk classify is adequate to reduce overtreatment of indolent cancers. We present and validate a gene expression signature that is highly specific for indolent disease and that, when combined with Gleason, improves upon the prognostic power of Gleason alone. Methods: A 30-gene signature of indolent disease was derived from a case-control sample of men (n=254) from the Health Professionals Follow-Up Study (HPFS) who were followed prospectively from cancer diagnosis for a median of 13.7 years. Cases were defined as men with prostate cancer who experienced a metastatic event or died of cancer during follow-up, while indolent controls survived at least 8 years without metastases. Whole-transcriptome gene expression was quantified from archival formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens acquired at prostatectomy. Genes were selected by a novel analytic strategy that maximizes a partial area under the curve (pAUC) to accurately identify indolent tumors. We validated the signature in two independent cohorts: the Physicians’ Health Study (PHS; n=150) and a Swedish Watchful Waiting cohort (WW; n=253) with respective median follow-up times of 14.4 and 9.0 years. Results: When compared to a model with Gleason alone, application of the signature to both validation data sets significantly improved prognostic accuracy as measured by pAUC (p=0.003 in PHS and p&lt;0.001 in WW). Performance was particularly strong among men diagnosed with Gleason 7, where unit standard deviation increases in the signature score were associated with odds ratios of indolence of 5.24 (95% CI 2.21-15.75; p&lt;0.001) and 2.37 (95% CI 1.45-4.19; p=0.001) in the PHS and WW cohorts, respectively. Conclusions: We present a signature of indolent prostate cancer that adds prognostic information beyond Gleason and has the potential to guide men to active surveillance and avoid overtreatment. Validation across both treated and untreated cohorts supports the discovery of a robust signature.
Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q.
Authors: A. F. List, A. Giagounidis, J. T. Backstrom, T. Fu, P. Fenaux
Journal: Journal of Clinical Oncology (2011)

6522 Background: Phase II multicenter, single-arm (MDS-003) and phase III multicenter, randomized, placebo-controlled (MDS-004) studies assessed LEN efficacy and safety in RBC transfusion dependent pts with IPSS Low-/Int-1-risk del5q MDS. Baseline (BL) thrombocytopenia (associated with reduced cumulative dosing) and transfusion burden > 4 units/8 wks were independent negative covariates for RBC-TI in MDS-003 (List A, et al. NEJM 2006;355:1456-65). Here we evaluate the predictive factors for durable RBC-TI in LEN-treated pts in MDS-003/-004 combined (N = 286). Methods: Pts received LEN 5 mg × 28 d, 10 mg × 21 d, or 10 mg × 28 d (all 28 d cycles). BL variables and total cycle 1 dose received were assessed in univariate (UV) models predicting RBC-TI ≥ 26 wks; significant factors were included in a multivariate (MV) logistic regression model. Duration of RBC-TI (Kaplan-Meier) by best cytogenetic response (CyR; IWG 2000) is shown. Results: Median follow-up was 166 (MDS-003) and 156 (MDS-004) wks. Higher BL platelet count and higher total cycle 1 dose received were significantly predictive of RBC-TI (Table). Negative predictive factors were higher BL transfusion burden and del5q + ≥ 1 abn. Total cycle 1 dose received directly correlated with CyR (OR 1.089, P < .0001). Pts with CyR (complete, median 980 d and partial, median 935 d) had more durable RBC-TI than nonresponders (median 518 d; log rank test P = .0015). Conclusions: Total LEN dose received in cycle 1 is a key variable for RBC-TI and CyR that is limited by BL platelet count. RBC-TI was most durable in pts with CyR. Covariate* RBC-TI ≥ 26 wks UV MV OR P value OR P value Total cycle 1 dose received, × 10 mg 1.108 <0.0001 1.070 0.0014 Age (> 65 vs ≤ 65 y) 0.716 0.1734 Sex (male vs female) 0.717 0.1973 Time since diagnosis, y 0.987 0.6947 Transfusion burden, units/8 wks 0.821 <0.0001 0.861 0.0022 Platelets (≥ 150 vs < 150 × 109/L) 2.481 0.0008 1.662 0.0955 ANC, × 109/L 1.034 0.4970 Hemoglobin, g/dL 1.155 0.1687 Myeloblasts (≥ 5% vs < 5%) 0.753 0.3910 Cytopenias (2 or 3 vs 1) 0.820 0.4110 del5q (+ ≥ 1 abn vs isolated) 0.525 0.0197 0.532 0.0375 Abbreviations: abn, abnormality; OR, odds ratio. * Variables are BL and continuous except when specified.